ISLA, D. et al. Abordaje terapéutico del carcinoma de pulmón no microcítico avanzado: ¿estamos "avanzando"?. []. , 28, 7, pp.11-20. ISSN 0378-4835.

Chemotherapy has a place in the treatment of advanced non-small cell lung cancer achieving a palliation of the disease-related symptoms and a small but consistent survival benefit. At present, the first line treatment is based on third generation drugs doublets with or without platinum. Targeted therapies seem promising because of their activity and tolerance. Application of genomics to non-small cell lung cancer therapy represents also an interesting research way for personalized treatments. Second, third and more lines of treatment have to be considered, as well as adequate individualized treatments for performance status 2 and elderly patients. Sex-related differences have been determined in causation and results. Advances in the treatment of non-small cell lung cancer have certainly been achieved, although slowly. Investigation of more efficient drugs, selection of patients based on clinical factors and tumor biology, and the optimal way to combine the different therapeutic modalities, are to be the priority for future trials.

: Advanced non-small cell lung cancer; Treatment; Advances.

        · |     · |     · ( pdf )